Back to journals
Academic Journal

CNS Drugs

5 Papers Indexed in Blossom

Data updated

Research Footprint

CNS Drugs has 5 tracked papers indexed in Blossom (2018–2026) from 34 authors, most often covering Ketamine, Esketamine and 5-MeO-DMT, across Depressive Disorders, Major Depressive Disorder (MDD) and Suicidality.

Published Papers

Open Accessindividual

Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial

This open-label phase 2a trial (n=12) tested a single intranasal dose of 5-MeO-DMT given alongside stable SSRI treatment in adults with treatment-resistant depression and found it was generally well tolerated, with mostly short-lived nasal and stomach side effects. Depressive symptoms fell quickly and stayed lower over 12 weeks in both dose groups.

Published
Journal
CNS Drugs
Authors
Seynaeve, M., Dunbar, F., Hindocha, C., Ermakova, A. O., Pierce, M., Conley, R. R., Roberts, C.
Open Accessindividual

Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study

This subgroup analysis of SUSTAIN-3 (n=96) studies patients with treatment-resistant depression (TRD) who received a second induction and maintenance treatment with esketamine nasal spray (ESK) plus oral antidepressant (AD) after a relapse in SUSTAIN-1.

Published
Journal
CNS Drugs
Authors
Castro, M., Wilkinson, S. T., Al Jurdi, R. K., Petrillo, M. P.z, Sun, L., Zaki, N., Borentain, S., Turkoz, I., Brown, B., Cabrera, P., Fu, D. J.
Open Accessindividual

Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant

This post hoc analysis of the TRANSFORM-2 trial assessed the effects of esketamine plus an oral antidepressant (AD) using the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS). The odds of improving in those treated with esketamine plus AD were at least two times greater than with placebo plus AD.

Published
Journal
CNS Drugs
Authors
Floden, L., Hudgens, S., Jamieson, C., Popova, V., Drevets, W. C., Cooper, K., Singh, J.
Open Accessmeta

Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies

This review (2020) identified 15 studies (n=178) that used a variety of psychedelics to have overlapping therapeutic processes, were compared favorably over conventional treatments and often elicited other positive changes beyond the specific diagnosis.

Published
Journal
CNS Drugs
Authors
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., Schoevers, R. A.
Open Accessmeta

Convergent Mechanisms Underlying Rapid Antidepressant Action

This review (2018) investigates the multiple mechanisms through which ketamine elicits its quick antidepressant effects.

Published
Journal
CNS Drugs
Authors
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A. G., Gould, T. D.

Quick Facts

Papers Indexed
5
h-Index
132
Open Access
No
Publisher
Adis International
Country
Switzerland
Website
Visit